The metabolism of clopidogrel: CYP2C19 is a minor pathway
NF Ford - The Journal of Clinical Pharmacology, 2016 - Wiley Online Library
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway
NF Ford - Journal of clinical pharmacology, 2016 - pubmed.ncbi.nlm.nih.gov
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
NF Ford - Journal of Clinical Pharmacology, 2016 - europepmc.org
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
NF Ford - Journal of Clinical Pharmacology, 2016 - search.ebscohost.com
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway
NF Ford - The Journal of Clinical Pharmacology, 2016 - infona.pl
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …
(CES1), forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …